Abstract
Thapsigargin was originally isolated from the roots of the Mediterranean umbelliferous plant Thapsia garganica in order to characterize the skin irritant principle. Characteristic chemical properties and semi-syntheses are reviewed. The biological activity was related to the subnanomolar affinity for the sarco/endoplasmic reticulum calcium ATPase. Prolonged inhibition of the pump afforded collapse of the calcium homeostasis and eventually apoptosis. Structure-activity relationships enabled design of an equipotent analogue containing a linker. Conjugation of the analogue containing the linker with peptides, which only are substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) enabled design of prodrugs targeting a number of cancer diseases including prostate cancer (G115) and hepatocellular carcinoma (G202). Prodrug G202 has under the name of mipsagargin in phase II clinical trials shown promising properties against hepatocellular carcinoma.
Keywords: Thapsigargin, mipsagargin, drug development, clinical trials, structure activity relationships, prostate specific antigen, prostate specific membrane antigen, prodrug, anti-angiogenesis.
Current Pharmaceutical Design
Title:Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development
Volume: 21 Issue: 38
Author(s): Nhu Thi Quynh Doan and Soren Brogger Christensen
Affiliation:
Keywords: Thapsigargin, mipsagargin, drug development, clinical trials, structure activity relationships, prostate specific antigen, prostate specific membrane antigen, prodrug, anti-angiogenesis.
Abstract: Thapsigargin was originally isolated from the roots of the Mediterranean umbelliferous plant Thapsia garganica in order to characterize the skin irritant principle. Characteristic chemical properties and semi-syntheses are reviewed. The biological activity was related to the subnanomolar affinity for the sarco/endoplasmic reticulum calcium ATPase. Prolonged inhibition of the pump afforded collapse of the calcium homeostasis and eventually apoptosis. Structure-activity relationships enabled design of an equipotent analogue containing a linker. Conjugation of the analogue containing the linker with peptides, which only are substrates for either prostate specific antigen (PSA) or prostate specific membrane antigen (PSMA) enabled design of prodrugs targeting a number of cancer diseases including prostate cancer (G115) and hepatocellular carcinoma (G202). Prodrug G202 has under the name of mipsagargin in phase II clinical trials shown promising properties against hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Quynh Doan Thi Nhu and Christensen Brogger Soren, Thapsigargin, Origin, Chemistry, Structure-Activity Relationships and Prodrug Development, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002112824
DOI https://dx.doi.org/10.2174/1381612821666151002112824 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of a New <sup>99m</sup>Tc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection
Anti-Cancer Agents in Medicinal Chemistry Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Regulation by Antioxidant Compounds: New Therapeutic Tools for Hypercholesterolemia?
Current Molecular Medicine Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-angiogenesis and Vessel Normalization
Current Gene Therapy The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy The Place of the Bioisosteric Sila-Substitution in Drug Design
Drug Design Reviews - Online (Discontinued) Early-Life Stress and Psychiatric Disorders: Epidemiology, Neurobiology and Innovative Pharmacological Targets
Current Pharmaceutical Design Furan-induced Oxidative Stress and DNA Damage in Diabetic and Nondiabetic Rats’ Blood and Protective Effect of Lycopene
Current Nutrition & Food Science 3,4,5-Trisubstituted-1,2,4-triazole Derivatives as Antiproliferative Agents: Synthesis, In vitro Evaluation and Molecular Modelling
Letters in Drug Design & Discovery Antinociceptive Effects of VV-Hemorphin-5 Peptide Analogues Containing Amino phosphonate Moiety in Mouse Formalin Model of Pain
Protein & Peptide Letters Advances in Nanocarriers for Anticancer Drugs Delivery
Current Medicinal Chemistry Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Potential Uses of MicroRNA in Lung Cancer Diagnosis, Prognosis, and Therapy
Current Cancer Drug Targets Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments
Current Clinical Pharmacology Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology Platelet Biomarkers in Tumor Growth
Current Proteomics PET Imaging in Prostate Cancer: Focus on Prostate-Specific Membrane Antigen
Current Topics in Medicinal Chemistry